Clinical trials: Advanced Malignant Cancer, open to volunteers
Advanced Solid Tumor
Platform Study of VSV-Based Recombinant Oncolytic Viruses for the Treatment of Advanced Malignant Tumors
To evaluate the safety and tolerability of combined administration of VSV injection solutions carrying different targets via multiple routes for treating advanced malignant solid tumors.
- Trial name
- NCT07656116
- Testing
- VSV injection
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Malignant Tumors
A Clinical Trial Evaluating Injection of TQB6411 in Subjects With Advanced Malignant Tumors
TQB6411 for injection is an antibody-conjugated drug (ADC) targeting EGFR/c-Met. After injecting blood intravenously, the antibody part of this product binds to the surface of EGFR and c-Met on tumor cells to block the activation…
- Trial name
- NCT07043751
- Testing
- TQB6411 injection
- Where
- 19 sites in China
- Volunteers
- 216 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Advanced Cancer, Pain
Integrated Smartphone Technology to Alleviate Malignant Pain (I-STAMP) Testing
The purpose of the study is to evaluate if the smartphone app, I-STAMP (Integrated Smartphone Technology to Alleviate Malignant Pain), helps participants with cancer pain manage symptoms and keep track of medications.
- Trial name
- NCT06117709
- Testing
- I-STAMP
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Dana-Farber Cancer Institute
Advanced Malignant Solid Tumor, Solid Tumor Cancer
A First in Human Study of PLT012 in Participants With Solid Tumor Cancers
The goal of this clinical trial is to learn about what doses of PLT012 are safe to use in adults with advanced cancers in solid tumors. It will also learn about how effective different doses of PLT012 are in treating cancer.
- Trial name
- NCT07337525
- Testing
- PLT012
- Where
- 4 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pilatus Biosciences Inc
Malignant Germ Cell Tumor, Lung Adenocarcinoma
DBC-664 in Adult Patients With Solid Tumors
DBC-664-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamic, and preliminary anti-tumor activity of DBC-664 in patients with endometrial cancer, ovarian…
- Conditions
- Malignant Germ Cell Tumor, Lung Adenocarcinoma, Gastric/Esophageal/Gastroesophageal Junction (GEJ) Adenocarcinoma, Urothelial Carcinoma
- Trial name
- NCT07705035
- Testing
- DBC-664
- Where
- 7 sites in United States
- Volunteers
- 210 people
- Sponsor
- Duboce Biopharmaceuticals, Inc.
Endometrial Cancer, Cervical Cancer
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Conditions
- Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
- Trial name
- NCT06293898
- Testing
- BL-M07D1
- Where
- 26 sites in United States
- Volunteers
- 280 people
- Sponsor
- SystImmune Inc.
Cancer, Cancer (Solid Tumors)
A Phase 1 Study of JMT108 in Participants With Advanced Solid Tumors
The goal of this clinical trial is to test JMT108, a type of drug called a bispecific antibody in adult patients with locally advanced or metastatic solid tumors.
- Trial name
- NCT07317505
- Testing
- JMT108
- Where
- 3 sites in United States
- Volunteers
- 270 people
- Sponsor
- Conjupro Biotherapeutics, Inc.
Gastric Cancer, Colon Cancer
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
This study is a open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CART cell preparations, and to reliminarily observe the study drug in CEA-positive advanced…
- Conditions
- Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer
- Trial name
- NCT06126406
- Testing
- CEA-targeted CAR-T cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Solid Tumor
A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors
This is a multicenter, open-label, phase I/Ⅱ study to evaluate the safety, efficacy, and pharmacokinetic (PK)/pharmacodynamic(PD) characteristics of HY0001a for injection in participants with advanced solid tumors.
- Trial name
- NCT07069062
- Testing
- Test product HY0001a for injection
- Where
- China
- Volunteers
- 261 people
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
NSCLC
Safety and Efficacy of NK510 to Treat NSCLC
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural…
- Trial name
- NCT06097962
- Testing
- NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
Advanced Solid Tumor
Phase I Study of In Vivo CAR-Tumor Technology for the Treatment of Advanced Malignant Tumors
This study is a single-arm, open-label, dose-escalation platform clinical trial designed to evaluate the safety, tolerability, efficacy, pharmacokinetic and pharmacodynamic characteristics of CAR-Tumour oncolytic virus as a…
- Trial name
- NCT07859462
- Testing
- CAR-Tumor05, CAR-Tumor 05, CAR-Tumor M01
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
B-cell Malignancies, Solid Tumors
Evaluation of SYS6005 in Patients With Advanced Malignant Tumor
This Phase I, open-label, multicenter study evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of SYS6005 in advanced malignancies, comprising dose-escalation and expansion phases.
- Trial name
- NCT06958679
- Testing
- SYS6005
- Where
- China
- Volunteers
- 132 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
NSCLC, SCLC
Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study
This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research.
- Conditions
- NSCLC, SCLC, Colorectal Cancer, Pancreas Cancer
- Trial name
- NCT06534762
- Testing
- Mirabegron
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Zhejiang Provincial People's Hospital
Advanced Malignant Tumors
A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors
This is a Phase 1/2, open-label, dose escalation and dose expansion study designed to characterize the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of IBB0979 in previously treated patients with…
- Trial name
- NCT05991583
- Testing
- IBB0979
- Where
- China
- Volunteers
- 25 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Advanced Solid Tumors, Malignant Neoplasm
A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010)
Researchers are looking for new ways to treat certain types of advanced solid tumors. Solid tumors are cancers mostly in organs and tissues in the body, not in the blood or other fluids.
- Trial name
- NCT07785609
- Testing
- MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist
- Where
- 4 sites in United States, Hong Kong and 1 more
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
MTD
A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors
Primary Objectives Dose escalation phase To evaluate the safety and tolerability of IBD0333 in patients with locally advanced/metastatic solid tumor or non-Hodgkin lymphoma and to determine the maximum tolerated dose (MTD)…
- Trial name
- NCT06292208
- Testing
- IBD0333
- Where
- China
- Volunteers
- 48 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
This phase I trial tests the safety, side effects, and best dose of pidnarulex in combination with trastuzumab deruxtecan in treating patients with breast cancer and other solid tumors that express varying levels of a protein…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma
- Trial name
- NCT07137416
- Testing
- Biopsy Procedure, Biospecimen Collection, Echocardiography Test
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors
A Clinical Trial of SIBP-A19 Injection in the Treatment of Advanced Malignant Solid Tumor Patients
To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A19 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).
- Trial name
- NCT06990464
- Testing
- SIBP-A19
- Where
- China
- Volunteers
- 156 people
- Sponsor
- Shanghai Institute Of Biological Products
Advanced Pancreatic Carcinoma, Advanced Gastric Carcinoma
Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T
The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in…
- Trial name
- NCT05620732
- Testing
- Claudin18.2 CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen University General Hospital
Neoplasms, Prostatic Neoplasms, Castration-Resistant
HTL0039732 in Participants With Advanced Solid Tumours
The purpose of this trial is to evaluate a new drug, HTL0039732, that will be administered on its own (as a monotherapy) and in combination with atezolizumab or with other approved anti-cancer therapies, in participants with…
- Conditions
- Neoplasms, Prostatic Neoplasms, Castration-Resistant, Stomach Neoplasms, Esophageal Neoplasms
- Trial name
- NCT05944237
- Testing
- HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion
- Where
- 6 sites in United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cancer Research UK